Ovulation suppression of premenstrual symptoms using oral contraceptives.

Patricia J. Sulak
In: The American journal of managed care · 2005 · vol. 11(16 Suppl) , pp. S492–7 · PMID:16336058 · W2104288597
article OA: closed CC0
View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-07, 2026-07-15 ⓘ

Combination oral contraceptives, especially newer formulations with reduced hormone levels and monthly regimens, offer a promising alternative for alleviating severe premenstrual symptoms by inhibiting ovulation.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Managing premenstrual symptoms at the most fundamental level necessitates careful consideration of female reproductive biology. Inhibiting ovulation using hormonal agents is a reasonable approach for reducing premenstrual symptoms, but the benefits of agents such as gonadotropin-releasing hormone agonists and the synthetic androgen danazol are largely offset by their adverse effects and costs. Combination oral contraceptives provide an alternative that is widely accepted by women experiencing premenstrual symptoms and by their physicians; and newer formulations with lower levels of estrogen and progestin, administered using a monthly regimen with a shortened pill-free interval, appear promising for alleviating patient distress from severe premenstrual symptoms.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (11)

Source provenance

openalex
last seen: 2026-05-10T11:57:47.865992+00:00
License: CC0 · commercial use OK